Agios Pharmaceuticals Files 8-K with Material Agreement
Ticker: AGIO · Form: 8-K · Filed: May 28, 2024 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | 8-K |
| Filed Date | May 28, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $905,000,000, $1 billion, $200 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
Agios signed a big deal, filing an 8-K. Details TBD.
AI Summary
On May 24, 2024, Agios Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported on other events and filed financial statements and exhibits as part of this 8-K filing. The specific details of the agreement and the nature of the other events are not elaborated upon in the provided text.
Why It Matters
This filing indicates a significant new agreement for Agios Pharmaceuticals, which could impact its business operations, financial performance, and strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which often carries significant implications and potential risks that are not fully detailed in the initial report.
Key Players & Entities
- Agios Pharmaceuticals, Inc. (company) — Registrant
- May 24, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Agios Pharmaceuticals?
The provided text states that Agios Pharmaceuticals, Inc. entered into a Material Definitive Agreement on May 24, 2024, but does not specify the details of this agreement.
What other items are reported in this 8-K filing besides the material agreement?
In addition to the Material Definitive Agreement, the filing also reports on 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 24, 2024.
What is the principal executive office address for Agios Pharmaceuticals, Inc.?
The principal executive offices of Agios Pharmaceuticals, Inc. are located at 88 Sidney Street, Cambridge, MA 02139.
What is the Commission File Number for Agios Pharmaceuticals, Inc.?
The Commission File Number for Agios Pharmaceuticals, Inc. is 001-36014.
Filing Stats: 798 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2024-05-28 07:09:32
Key Financial Figures
- $0.001 — ich registered Common Stock, Par Value $0.001 per share AGIO Nasdaq Global Select
- $905,000,000 — nd the Purchaser agreed to purchase for $905,000,000, the Company's rights to an earn-out eq
- $1 billion — nts made by Servier on account of up to $1 billion in net sales for each calendar year. An
- $200 million — hts to a potential milestone payment of $200 million from Servier upon approval of vorasiden
Filing Documents
- d717537d8k.htm (8-K) — 27KB
- d717537dex991.htm (EX-99.1) — 12KB
- g717537g0523104156625.jpg (GRAPHIC) — 3KB
- 0001193125-24-147583.txt ( ) — 165KB
- agio-20240524.xsd (EX-101.SCH) — 3KB
- agio-20240524_lab.xml (EX-101.LAB) — 17KB
- agio-20240524_pre.xml (EX-101.PRE) — 11KB
- d717537d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued May 28, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGIOS PHARMACEUTICALS, INC. Date: May 28, 2024 By: /s/ Brian Goff Brian Goff Chief Executive Officer